NVCT - NASDAQ
Nuvectis Pharma, Inc.
$9.42
-0.95%Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
At a Glance
Live Snapshotnvct
Total Liabilities
Last Annual Value
13.30M
3-Year CAGR
29%
5-Year CAGR
321%
10-Year CAGR
105%
Nuvectis Pharma, Inc. Competitors Analysis of Total Liabilities
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Nuvectis Pharma, Inc. NASDAQ:NVCT | 13.30M | 23.9% | -5.5% | N/A | |
 Alto Neuroscience, Inc. NYSE:ANRO | 33.55M | -40.4% | -4.1% | N/A | |
 C4 Therapeutics, Inc. NASDAQ:CCCC | 102.49M | -7.7% | -2.6% | N/A | |
 PepGen Inc. NASDAQ:PEPG | 26.46M | -8.6% | 20.2% | N/A | |
 Actuate Therapeutics Inc NASDAQ:ACTU | 6.11M | -60.9% | N/A | N/A | |
 Atossa Therapeutics, Inc. NASDAQ:ATOS | 8.26M | 16.4% | 21.4% | 22.9% | |
 Greenwich LifeSciences, Inc. NASDAQ:GLSI | 2.02M | 89.9% | 39.2% | N/A | |
 Tevogen Bio Holdings Inc. NASDAQ:TVGN | 10.14M | -53.4% | -15.9% | N/A | |
 Cardiff Oncology, Inc. NASDAQ:CRDF | 16.50M | 11.5% | 12.6% | -3.8% | |
 Rani Therapeutics Holdings, Inc. NASDAQ:RANI | 17.11M | -19.2% | 45.3% | N/A | |
 Tonix Pharmaceuticals Holding Corp. NASDAQ:TNXP | 32.02M | -13.2% | 7.6% | 31.0% |
Nuvectis Pharma, Inc. Fair Value Envelope
Related Guides
Continue your NVCT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.